R-CDOP regimen
WikiDoc Resources for R-CDOP regimen |
Articles |
---|
Most recent articles on R-CDOP regimen Most cited articles on R-CDOP regimen |
Media |
Powerpoint slides on R-CDOP regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on R-CDOP regimen at Clinical Trials.gov Trial results on R-CDOP regimen Clinical Trials on R-CDOP regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on R-CDOP regimen NICE Guidance on R-CDOP regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on R-CDOP regimen Discussion groups on R-CDOP regimen Patient Handouts on R-CDOP regimen Directions to Hospitals Treating R-CDOP regimen Risk calculators and risk factors for R-CDOP regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for R-CDOP regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
R-CDOP regimen refers to a regimen consisting of rituximab, cyclophosphamide, liposomal doxorubicin (Caelyx), vincristine, prednisone used to treat non-Hodgkin lymphoma.[1]
Regimen
RRituximab
CCyclophosphamide
DDoxorubicin (Caelyx)
OVincristine (Oncovin)
PPrednisone
Indications
References
- ↑ 1.0 1.1 Martino R, Perea G, Caballero MD, Mateos MV, Ribera JM, de Oteyza JP; et al. (2002). "Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study". Haematologica. 87 (8): 822–7. PMID 12161358.